var data={"title":"Selexipag: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Selexipag: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/792364?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=selexipag-patient-drug-information\" class=\"drug drug_patient\">see &quot;Selexipag: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46021657\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Uptravi</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45824871\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Prostacyclin;</li>\n      <li>\n        Prostacyclin IP Receptor Agonist;</li>\n      <li>\n        Vasodilator</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46037768\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Pulmonary arterial hypertension:</b> Oral: Initial: 200 mcg twice daily; increase by 200 mcg twice daily, usually at weekly intervals, to the highest tolerated dose (maximum dose: 1,600 mcg twice daily). If a dose is not tolerated, reduce dose to previously tolerated dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Missed dose:</i> If dose is missed, take dose as soon as possible unless the next dose is within the next 6 hours. If &ge;3 days of treatment are missed, restart at a lower dose and then retitrate.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46037769\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46037770\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glomerular filtration rate (estimated) &ge;15 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glomerular filtration rate (estimated) &lt;15 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dialysis: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46037771\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild hepatic impairment (Child-Pugh class A): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moderate hepatic impairment (Child-Pugh class B): Initial: 200 mcg once daily; may increase by 200 mcg once daily at weekly intervals, as tolerated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe hepatic impairment (Child-Pugh class C): Avoid use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46021658\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Uptravi: 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1000 mcg, 1200 mcg, 1400 mcg, 1600 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Therapy Pack, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Uptravi: 200 mcg (140s) and 800 mcg (60s) (200 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46021656\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46037773\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer with or without food; tolerability may be improved when taken with food. Swallow tablets whole; do not split, crush, or chew. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45824872\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Pulmonary arterial hypertension:</b> Treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45839533\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Flushing (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (65%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (42%), nausea (33%), vomiting (18%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Jaw pain (26%), limb pain (17%), myalgia (16%), arthralgia (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hyperthyroidism (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Decreased appetite (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Decreased hemoglobin (below 10 g/dL: 9%), anemia (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Symptomatic hypotension</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45824873\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Concomitant use with strong CYP2C8 inhibitors (eg, gemfibrozil).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindication (not in US labeling): Hypersensitivity to selexipag or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46037753\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary edema: If signs/symptoms of pulmonary edema occur, consider the possibility of associated pulmonary veno-occlusive disease (PVOD). If PVOD is confirmed, discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with moderate hepatic impairment (dosage modification is recommended); avoid use in patients with severe hepatic impairment (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45839472\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of BCRP/ABCG2, CYP2C8 (major), CYP3A4 (minor), OATP1B1/SLCO1B1, OATP1B3/SLCO1B3; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45839469\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=106041&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP2C8 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C8 Inhibitors (Moderate): May increase serum concentrations of the active metabolite(s) of Selexipag. CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Selexipag. Management: If initiating selexipag in a patient on a moderate CYP2C8 inhibitor, consider a less frequent dosing regimen (ie, once daily). If initiating a moderate CYP2C8 inhibitor in a patient on selexipag, consider a selexipag dose reduction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C8 Inhibitors (Strong): May increase serum concentrations of the active metabolite(s) of Selexipag. CYP2C8 Inhibitors (Strong) may increase the serum concentration of Selexipag.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May increase the serum concentration of CYP2C8 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor may decrease the serum concentration of CYP2C8 Substrates (High Risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP2C8 Substrates (High risk with Inhibitors). Management: Use CYP2C8 substrates at the lowest recommended dose, and monitor closely for adverse effects (including myopathy), during and in the 2 weeks following mifepristone treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease serum concentrations of the active metabolite(s) of Selexipag.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46037751\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Women with pulmonary arterial hypertension (PAH) are encouraged to avoid pregnancy (McLaughlin 2009). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46037752\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if selexipag is present in breast milk. Due to the potential for serious adverse reactions in the breastfeeding infant, the manufacturer recommends a decision be made to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46037775\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Liver function tests. Monitor for signs of pulmonary edema and for improvements in pulmonary function, exercise tolerance, and quality of life.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46037756\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Selexipag is a selective prostacyclin IP receptor agonist. Prostacyclin is produced in the endothelial cells and induces vasodilation; also inhibits platelet aggregation. Patients with pulmonary arterial hypertension appear to have a dysregulation in the prostacyclin metabolic pathways (Galie 2013). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46037758\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid (Kaufmann 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: 11.7 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~99%; to albumin and alpha-1 acid glycoprotein</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP3A4, CYP2C8, UGT1A3 and UGT2B7; hydrolyzed by carboxylesterase 1 to the active metabolite, ACT-333679, which is a major contributor to the activity (Kaufmann 2015); the active metabolite is then glucuronidated</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: ~49%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Terminal: Selexipag: 0.8 to 2.5 hours; Active metabolite: 6.2 to 13.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Selexipag: 1 to 3 hours; Active metabolite: 3 to 4 hours; Delayed with food</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (~93%); urine (12%; as inactive metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46105226\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet Therapy Pack</b> (Uptravi Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 &amp; 800 mcg (200): $29,610.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Uptravi Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg (60): $12,690.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mcg (60): $19,735.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mcg (60): $19,735.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mcg (60): $19,735.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mcg (60): $19,735.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1200 mcg (60): $19,735.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1400 mcg (60): $19,735.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1600 mcg (60): $19,735.20</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49940098\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Uptravi (AT, AU, CZ, DE, DK, EE, GB, HR, IE, IL, JP, KR, LT, LV, NO, NZ, PL, PT, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Gali&egrave; N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. <i>J Am Coll Cardiol</i>. 2013;62(25)(suppl):D60-D72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/selexipag-drug-information/abstract-text/24355643/pubmed\" target=\"_blank\" id=\"24355643\">24355643</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaufmann P, Okubo K, Bruderer S, et al. Pharmacokinetics and tolerability of the novel oral prostacyclin IP receptor agonist selexipag. <i>Am J Cardiovasc Drugs</i>. 2015;15(3):195-203.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/selexipag-drug-information/abstract-text/25850750/pubmed\" target=\"_blank\" id=\"25850750\">25850750</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. <i>J Am Coll Cardiol</i>. 2009;53(17):1573&ndash;1619.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/selexipag-drug-information/abstract-text/19389575/pubmed\" target=\"_blank\" id=\"19389575\">19389575</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. <i>N Engl J Med</i>. 2015;373(26):2522-2533.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/selexipag-drug-information/abstract-text/26699168/pubmed\" target=\"_blank\" id=\"26699168\">26699168</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Uptravi (selexipag) [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US Inc; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Uptravi (selexipag) [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US Inc; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Uptravi (selexipag) [product monograph]. Laval, Quebec, Canada: Actelion Pharmaceuticals Canada Inc; August 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 106041 Version 35.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F46021657\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F45824871\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F46037768\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F46037769\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F46037770\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F46037771\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F46021658\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F46021656\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F46037773\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F45824872\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F45839533\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F45824873\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F46037753\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F45839472\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F45839469\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F46037751\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F46037752\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F46037775\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F46037756\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F46037758\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F46105226\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F49940098\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/106041|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=selexipag-patient-drug-information\" class=\"drug drug_patient\">Selexipag: Patient drug information</a></li></ul></div></div>","javascript":null}